Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis

INTRODUCTION: Randomized studies have shown that bortezomib (BTZ) can be given weekly via intravenous (IV) route or twice weekly via subcutaneous (SC) route with lower neuropathy risk and no loss of anti-myeloma efficacy compared to original standard IV twice weekly schedule. Weekly SC should theref...

Descripción completa

Detalles Bibliográficos
Autores principales: Sidana, Surbhi, Narkhede, Mayur, Elson, Paul, Hastings, Debbie, Faiman, Beth, Valent, Jason, Samaras, Christy, Hamilton, Kimberly, Liu, Hien K., Smith, Mitchell R., Reu, Frederic J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344345/
https://www.ncbi.nlm.nih.gov/pubmed/28278302
http://dx.doi.org/10.1371/journal.pone.0172996

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344345/
https://www.ncbi.nlm.nih.gov/pubmed/28278302
http://dx.doi.org/10.1371/journal.pone.0172996

Ejemplares similares